Penn Medicine’s 6th Annual 5K for the IOA & Memory Mile Walk

It was a warm Fall morning on Sunday, September 24, 2017 as 371 runners and walkers and 70 volunteers gathered for Penn Medicine’s 6th Annual 5K for the IOA and Memory Mile Walk.

The fundraiser, which takes place throughout Penn Park and the University of Pennsylvania campus, raised a total of $49,260 this year for Alzheimer’s and aging-related disease research efforts at Penn’s Institute on Aging.

In addition to its usual run and walk, the event also included pre and post-race yoga sessions, entertainment provided by DeeJay007, and photobooth fun for the whole family. This year’s overall male winner, Alexis Tingan (pictured below, left), finished the race in 17 minutes and 35 seconds, with the overall female winner, Sara McCuaig (pictured below, right), not far behind him with a time of 19 minutes and 24 seconds.

To view the full list of race results, click here.

Last week, CBS Philly interviewed PJ Brennan, MD, Chief Medical Officer at Penn Medicine who created the event in memory of his father who lost his battle with Alzheimer’s disease. “I thought it would be a fun way to get my community here together and bring some attention to the work that the Institute on Aging does and raise some money for this novel research,” said Brennan during the interview.

To view more photos of the event, click here.

Advertisements

Eliezer Masliah, MD, Director of NIA’s Division of Neuroscience visits Penn

EliezerMasliah_Flyer5217On Tuesday, May 2, 2017, Eliezer Masliah, MD*, Director of the National Institute on Aging’s (NIA) Division of Neuroscience, paid a visit to the University of Pennsylvania’s Institute on Aging (IOA), Center for Neurodegenerative Disease Research (CNDR), and Penn Neurodegeneration Genomics Center (PNGC).

The reason for Dr. Masliah’s visit was not just to learn about the neurodegenerative disease and aging-related research that is taking place in these centers here at Penn, but also to see how they all collaborate and work toward mutual goals. This gave him the opportunity to see firsthand how NIA and National Institutes of Health (NIH) funding is being used and made worthwhile to support the groundbreaking work of these centers.

Several topics were covered during the visit including the inception and mission of the new Penn Neurodegeneration Genomics Center (PNGC), directed by Gerard D. Schellenberg, PhD, and its five NIH-funded projects, the Alzheimer’s Disease Genetics Consortium (ADGC), Alzheimer’s Disease Sequencing Project (ADSP), Consortium for Alzheimer’s Sequence Analysis (CASA), Center for Genetics and Genomics of Alzheimer’s Disease (CGAD), and the NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS). Dr. Schellenberg and other PNGC members, including co-director Li-San Wang, PhD, associate professor of Pathology and Laboratory Medicine and principal investigator of NIAGADS, presented some of the current work and future plans for PNGC to achieve their overarching goal to “completely resolve the genetics of Alzheimer’s disease.”

After the morning session, Dr. Masliah joined John Q. Trojanowski, MD, PhD, Director of the IOA, and Virginia M.-Y. Lee, PhD, Director of CNDR, with several of their lab members as well as several Penn faculty working in neurodegeneration, for an open discussion on the multidisciplinary approach of the IOA and CNDR. A key feature of these centers is their ability to collaborate across many different disciplines within the University of Pennsylvania’s Perelman School of Medicine. This includes faculty members from several different departments such as Pathology and Laboratory Medicine, Neurology, Psychiatry, Geriatric Medicine, and Epidemiology to name a few.

Among the many topics discussed, one that was of particular interest to Dr. Masliah was the large number of young investigators and finding out what it was that attracted them to Penn. Many of the lab members were eager to participate and to share their outlook on why Penn was the right place to start their research career. Overall, they agreed that the collaborative, multidisciplinary nature of these centers is what appealed to them most. They also praised Penn for its training and the encouraging environment that it provides for applying for research grants and other funding opportunities. Additionally, Penn is well known for its state of the art databases and data sharing, providing top-notch integration and access to resources for its investigators. Dr. Masliah was especially impressed with CNDR’s Integrative Neurodegenerative Disease Database (INDD) which tracks nearly 17,000 patients and/or research subjects at Penn’s several neurodegenerative disease related centers.

The visit concluded with a lecture by Dr. Masliah, titled “Advancing the National Plan to Address AD through National and International Collaborations.” During his talk, Dr. Masliah discussed the recent $2 billion NIH budget increase which includes $400 million new Alzheimer’s disease funds, new NINDS funding opportunities in partnership with NIA on Lewy body dementia (LDB), and the 17 new Alzheimer’s disease FOA’s.

In terms of what to expect for the future, Dr. Masliah says to stay tuned for changes in pay-lines for FY17, more funding for fellowship and K awards, and more funded FOA’s and 27 new FOA’s.


* In his position as the Director of the NIA’s Division of Neuroscience, Dr. Masliah oversees the world’s largest research program on Alzheimer’s disease-related dementias and cognitive aging. He is an internationally renowned neuroscientist and neuropathologist and has approximately 800 original research articles and 70 book chapters. 

Delirium and Aging

screen-shot-2016-11-10-at-10-41-51-amDelirium, a medical condition characterized by acute confusion, disorientation, or other mental health disruptions that affect thinking and behavior, affects nearly 7 million hospitalized Americans annually. While this condition can occur at any age, it mainly affects individuals 65 years or older and is often misdiagnosed as dementia.

As stated in an article originally published by Kaiser Health News and shared by Next Avenue, “while delirium and dementia can coexist, they are distinctly different illnesses. Dementia develops gradually and worsens progressively, while delirium occurs suddenly and typically fluctuates during the course of a day.” Particularly susceptible patients are those on ventilators or being heavily sedated in intensive care units, as well as those recovering from surgery.

“After an older adult undergoes anesthesia, they can often experience postoperative delirium,” explained Lee A. Fleisher, MD, chair of Anesthesiology and Critical Care at Penn, in a recent Penn Medicine News Blog on postoperative delirium and the uncertainties of anesthesia. “Patients in this state may hallucinate, they may forget why they are in the hospital, or have difficulty communicating or understanding what is going on around them.”

However, delirium can also result from something as simple and easily treated as a urinary tract infection.

According to research published in 2009 and referenced by Next Avenue, an estimated 40% of delirium cases are actually preventable; yet, the underlying cause is still unknown.

With all of this in mind, health care professionals, government agencies, and related nonprofit organizations gathered at the American Society of Anesthesiologists’ Brain Health Summit to discuss, among other topics, the postoperative risks of delirium and delayed cognitive recovery and whether or not they are significant enough to include in consent and patient education materials. They also considered ways to reduce the risks and to increase research funding.

The Penn Medicine News Blog says that “while the Summit provided some direction and tactics for industry leaders to act upon, there are still other options that can be explored and implemented to advance learning, protect patients, and uncover the uncertainties around anesthesia and postoperative delirium.”

“Encouraging patients to follow a balanced diet and exercise regularly in the lead up to surgery, allowing patients to bring mementos and family photos to their hospital room after surgery, even asking families and caregivers to keep a close eye on small declines in patients’ cognitive function preoperatively – simple things like the patient not being as sharp as he or she once were – may help clinicians properly prepare for patient care, and may help patients readjust after surgery and avoid postoperative delirium,” Fleisher said. “While these have not been scientifically proven to help, we think that even the smallest measures may make a difference for patients who are coming out of anesthesia.”

To learn more about delirium and aging, join the Institute on Aging on Tuesday, April 18, 2017 for our Visiting Scholars Series lecture by Edward Marcantonio, MD, SM.

Dr. Marcantonio is the Section Chief for Research in the Division of General Medicine and Primary Care at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. His research concentrations focus on delirium and cognitive function.

For more information, visit: www.med.upenn.edu/aging/events


Photo credit: news.pennmedicine.org/blog

Penn Medicine Celebrates a Milestone with its 5th Annual 5K for the IOA and the Memory Mile Walk

On Sunday, September 25, 2016, Penn Medicine celebrated the 5th anniversary of its annual 5K for the IOA and Memory Mile Walk!

Nearly 500 runners, walkers, and spectators turned up bright and early for the 3.1-mile race through Penn Park and 1-mile walk across the University of Pennsylvania’s campus. The event continues to provide fun for the whole family, even your four-legged friends, and brings together hundreds of people for one universal cause — to support Alzheimer’s and aging-related research at Penn’s Institute on Aging (IOA).

penn-45

P.J. Brennan, MD, with his sister, Sheila Connor, at this year’s event.

The 5K for the IOA and the Memory Mile Walk was started in 2012 by the University of Pennsylvania Health System’s Chief Medical Officer and Senior Vice President and IOA External Advisory Board member, P.J. Brennan, MD. After losing his father to Alzheimer’s disease, Dr. Brennan wanted to create a way to get involved in the efforts of finding a cure for this devastating disease. “I wanted to provide support for investigators to test novel ideas that could someday lead to groundbreaking therapies,” he said.

This year, the event raised an impressive $34,245 for the cause and had one of its largest turnouts yet.

As the numbers continue to grow over the years, so do the reasons to attend. In addition to great “SWAG” bags and various raffle prizes, generous awards were given to the top male and female runners in each age category. The overall winners were James Murphy, age 25, with a time of 16:57 and Zandra Walton, age 28, with a  time of 19:19.

Video:

We would like to extend our sincerest gratitude to all of the race organizers, sponsors, volunteers, donors, and participants who make this event a success! Thank you!

The full list of race results, courtesy of Run the Day, can be found here.

To view all of the photos from the event, click here.

To view the 6ABC news coverage of the event, click here.

For more information, visit: www.pennmedicine.org/5kioa

Could this be the breakthrough that Alzheimer’s research has been waiting for?

News of success in a recent drug trial hit the media yesterday, showing some promise in the field of Alzheimer’s disease (AD) research. According to the paper published this week in Nature, scientists showed that by using high doses of an antibody called aducanumab that they were able to reduce the amount of amyloid plaques — a building block of Alzheimer’s disease — and essentially erase one of the visible signs of AD in the brain.

The study was conducted by scanning the brains of individuals diagnosed with mild to moderate Alzheimer’s disease in which participants were randomly selected to receive either a placebo or one of three doses of the antibody once a month over the course of a year. Results showed that those receiving the highest dosage showed the most reduction of amyloid with some also experiencing a slower rate of cognitive decline.

While this is not the first trial of its kind, one researcher on the study is very hopeful that this could be the breakthrough that Alzheimer’s research has been waiting for. “Compared to other studies published in the past, the effect size of this drug is unprecedented,” said Professor Roger Nitsch of Zurig University in an article issued by the Independent.

Kurt Brunden, PhD, director of Drug Discovery and research professor at Penn’s Center for Neurodegenerative Disease Research (CNDR), agrees that the current findings are encouraging, but believes more is needed to verify the true effectiveness.

BrundenKurt_hsThe Phase 1b clinical data obtained with aducanumab appear to be quite encouraging, with the apparent reduction in senile plaque burden as revealed by PET imaging being particularly noteworthy. However, this was a small trial that wasn’t designed to generate definitive data on improvement in patient cognitive performance. Thus, the results from ongoing larger clinical studies with this immunotherapeutic agent will be critical in demonstrating that a reduction in senile plaques in patients with mild cognitive impairments (MCI) or early AD results in an improvement in cognitive measures,” he explained.

Dr. Brunden’s work at CNDR focuses on overseeing research programs geared towards identifying therapeutic targets and potential treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. He is leading this year’s CNDR Marian S. Ware Research Retreat, which will cover the topic of Alzheimer’s and Parkinson’s Disease Drug Discovery and will feature a variety of presenters from Penn and beyond.

You can learn more about the aducanumab trial in this recently published article by TIME.

Penn Alzheimer’s Disease Core Center (ADCC) Receives $8.8 Million Renewal

It was announced today that the University of Pennsylvania’s Alzheimer’s Disease Core Center (ADCC) has officially been awarded a five year, $8.8 million renewal from the National Institute on Aging (NIA) at the National Institutes of Health (NIH) to continue investigating the progression, diagnostics, treatments, and strategies of Alzheimer’s disease and related dementias.

“We are hopeful our support for the Penn ADC research program will lead to novel findings on the basic mechanisms involved in these diseases, and innovative new programs aimed at improving the lives of those living with dementia and their caregivers,” explained Nina Silverberg, PhD, an Alzheimer’s Disease Centers program director at NIA, in the Penn Medicine announcement.

The Penn ADCC has a history of groundbreaking discoveries, including identifying the protein tau as the building block of neurofibrillary tangles, as well as the role of alpha-synuclein in forming the Lewy bodies that are found in Parkinson’s disease, Parkinson’s disease dementia, Lewy body dementia, and 50% of Alzheimer’s cases.

Learn more about the Penn ADCC in the video* below:

Read the full Penn Medicine Announcement here.

Visit the Penn ADCC website here.

* Steven Arnold, MD is no longer at the University of Pennsylvania. David A. Wolk, MD is now the Clinical Core leader for the Penn Alzheimer’s Disease Core Center (ADCC).

 

“To sleep, per chance to age… and avoid Alzheimer’s disease”: A recap of the 2016 Sylvan M. Cohen Annual Retreat

On Wednesday, June 8, 2016, the Institute on Aging hosted its annual Sylvan M. Cohen Retreat and Poster Session. This year’s retreat, titled “To sleep, per chance to age… and avoid Alzheimer’s disease,” was co-sponsored by Penn’s Center for Sleep and Circadian Neurobiology and explored the effects of sleep loss and it’s possible link to Alzheimer’s and other neurodegenerative conditions.

corrected_DJquoteAs usual, the event began with lunch and a series of lectures, but this year we had the pleasure of having J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine (PSOM), join us for opening remarks.

He expressed his excitement to see such collaboration amongst the two sponsoring centers and encouraged more of this, not only in the PSOM, but also across the University as a whole. “One of the secrets at Penn Medicine is that we have these catalytic centers and institutes and it’s even more impressive that there is often cross fertilization between them,” explained Dean Jameson.

corrected_DJquote&pic.png

Keynote speaker, David M. Holtzman, MD, professor and chairman, Department of Neurology at Washington University School of Medicine, kicked off the lectures by discussing his research in “Understanding the Relationships between Sleep, Protein Aggregation, and Alzheimer’s disease.”

Other topics, covered by our Penn Presenters, included (click for video interviews):

Immediately following the lectures, researchers from the University of Pennsylvania and beyond presented their current aging-related work at our annual Poster Session. Categories included basic science, clinical research, & education and community and awards were given to the top posters.

Poster Winners

BASIC SCIENCE

1st Place
BasicSciecne1Enhancing a WNT-telomere feedback loop restores intestinal stem cell function in a human organotypic model of dyskeratosis congenita
Presenter: Dong-Hun Woo
Authors: Dong-Hun Woo, Qijun Chen, Ting-Lin B. Yang, M. Rebecca Glineburg, Carla Hoge, Nicolae A. Leu, F. Brad Johnson, and Christopher J. Lengner

 

2nd Place
BasicSciecne2AB Plaques Mediate Neuritic Plaque-like Tau Pathology that is Distinct from Perikaryal Tau Inclusions
Presenters: Zhuohao He
Authors: Zhuohao He, Jing L. Guo, Jennifer D. McBride, Lakshmi Changolkar, Bin Zhang, Ronald J. Gathagan, Hyesung Kim, Sneha Narasimhan, Kurt R. Brunden, John Q. Trojanowski, Virginia M.-Y. Lee


CLINICAL RESEARCH and EDUCATION & COMMUNITY *

1st Place
ClinRes1Tau Pathology Influences Dementia Onset and Survival in Lewy Body Spectrum Disorders
Presenter: David Irwin
Authors: David J. Irwin, MD MSTR, Murray Grossman MD, Daniel Weintraub MD, Howard I. Hurtig MD, John E. Duda MD, Sharon X. Xie PhD, Edward B. Lee MD PhD, Vivianna M. Van Deerlin MD, PhD,Oscar L. Lopez MD, Julia K. Kofler MD, Peter T. Nelson, MD PhD, Randy Woltjer MD PhD, Joseph F. Quinn MD, Jeffery Kaye MD, James B Leverenz MD, Debby Tsuang MD, MSc, Katelan Longfellow MD, Dora Yearout BS, Walter Kukull PhD, C. Dirk Keene MD, PhD, Thomas J. Montine MD, PhD, Cyrus P. Zabetian MD MS, John Q. Trojanowski MD PhD

2nd Place
ClinRes2Clinical Profile of Older Adults with Mild or No Cognitive Impairment Who Receive Prescriptions for Cholinesterase Inhibitors and/or Memantine: A descriptive study from the PACE/PACENET BHL Caregiver Resources, Education and Support (CREST) Program
Presenter: Romika Dhar, MD
Authors: Romika Dhar, MD; Amy Benson, MSEd; Joel E. Streim, MD; David W. Oslin, MD

* Due to the number of posters submitted, the categories for Clinical Research and Education & Community were combined.

Screen Shot 2016-06-22 at 10.40.42 AM

To view some of the full lectures from our retreat, click here.
* Please note: Some of the lectures are not available to view due to unpublished data being presented *

View more photos from our 2016 Sylvan M. Cohen Retreat Facebook album here.